At the 21st Spinal Research Network Meeting, we had the pleasure of speaking with Grégoire Courtine to hear more about the development of neurotechnologies for spinal cord injuries, including how close we might be to turning this rehabilitation paradigm into a treatment in the clinic.
Researchers have discovered that a gene-editing technique, which silences gene transmitting pain signals, is effective in mice that had been suffering from the painful effects of chemotherapy.
This review article from the journal Pain Management provides a summary of national and international evidence-based guidelines for common pain conditions to guide primary healthcare practitioners on recommended non-prescription analgesic treatments.
Positive results for Emgality® (galcanezumab) have been reported from the CONQUER study in patients who failed previous migraine preventive treatments.
In this editorial, we shed light on the key advances made in migraine genetics, their neurobiology and what the future might hold for the field.
A drug belonging to a new generation of acute migraine headache treatments, termed rimegepant, has been demonstrated to eliminate pain and reduce bothersome symptoms.
Researchers have determined that CGRP exhibits pain effects in a sex-specific manner. Understanding these sex-specific differences could help us understand why migraines are three-times more common in women than in men.
Researchers have identified natural killer cells as a potential therapeutic target for the treatment of neuropathic pain. The immune cells can selectively degenerate axons, allowing repair of damaged nerves.
Researchers have developed an application that could detect when an opioid overdose has taken place; potentially leading to a greater number of individuals receiving medical help in this situation.
Scientists have created a vaccine containing monoclonal antibodies that are effective against several synthetic opioids, including carfentanil.